18F-FDG PET/CT versus diagnostic contrast-enhanced CT for follow-up of stage IV melanoma patients treated by tyrosine kinase or immune checkpoint inhibitors: frequency and management of discordances over a 3-year period in a university hospital

Jean-Baptiste Le Goubey1**, Charline Lasnon2,3*, Ines Nakouri1, Laure Césaire1, Michel dePontville1, Catherine Nganoa4, Diane Kottler1, Nicolas Aide2,5*

Diane Kottler and Nicolas Aide share senior authorship

** equally contributed

1Dermatology Department, University Hospital, Caen, France
2Nuclear Medicine Department, François Baclesse Cancer Centre, Caen, France
3INSERM ANTICIPE U 1086, Normandy University, Caen, France
4Nuclear Medicine Department, University Hospital, Caen, France
5Normandie University, Caen, France

* Prof. Nicolas Aide, M.D, PhD
Nuclear Medicine Department, University Hospital
Avenue Côte de Nacre,
14000 Caen Cedex 5, France
e-mail: aide-n@chu-caen.fr
Ph: +33 231063244
Fax: +33 231064927
ORCID: https://orcid.org/0000-0001-9207-0847

Received: date; Accepted: date; Published: date

Abstract:

Aim
To perform a comprehensive analysis of discordances between contrast-enhanced CT (ceCT) and 18F-FDG PET/CT in the evaluation of the extra-cerebral treatment monitoring in patients with stage IV melanoma.

Materials and methods
We conducted a retrospective monocentric observational study over a 3-years period in patients referred for 18F-FDG PET/CT and ceCT in the framework of therapy monitoring of immune checkpoint or tyrosine kinase inhibitors (ICIs or TKIs) as of January-2017. Imaging reports were analysed by two physicians in consensus. Anatomical site responsible for discordances, as well as induced changes in treatment were noted.

Results
Eighty patients were included and 195 pairs of scans analysed. Overall, discordances occurred in 65 cases (33%). Eighty percent of the discordances (52/65) were due to 18F-FDG PET/CT scans upstaging the patient. Amongst these discordances, 17/52 (33%) led to change in patient’s management, the
most frequent being radiotherapy of a progressing site. ceCT represented 13/65 (20%) of discordances and induced changes in patients’ management in 2/13 cases (15%). The more frequent anatomical site involved was subcutaneous for 18F-FDG PET/CT findings and lung or liver for ceCT.

Conclusions
Treatment monitoring with 18F-FDG PET/CT is more efficient and has a greater impact in patient’s management than ceCT.

Keywords: 18F-FDG PET/CT; contrast-enhanced CT; melanoma; metastases; tyrosine kinase inhibitors; Immune checkpoint inhibitors; follow-up; therapy monitoring

1. Introduction

Cutaneous melanoma (CM) is an aggressive skin tumour with a high risk of visceral metastasis with a five-year relative survival rates of about 16% in metastatic cases [1]. The incidence of melanoma is increasing worldwide in white populations and is predicted to continue to increase for decades [2].

Over the last 10 years, the emergence of new therapeutics has considerably changed the prognosis of metastatic or unresectable melanoma with a marked improvement of survival compared to the era of chemotherapy [3-5]. Two main types of systemic treatments are now available depending on the BRAF V600 mutational status of the disease. On one hand, combination of targeted therapy (TT) with BRAF and MEK inhibitors can be proposed for patients with a BRAF V600 mutation-bearing tumour. On the other hand, immunotherapy (IT) with immune checkpoint inhibitor targeting antiprogrammed death 1 (PD-1) or anticytotoxic T-lymphocyte antigen 4 (CTLA-4) are proposed, single or combined, regardless of the BRAF status. These therapeutic advances have led to a profound change in the management of treatment with the possibility of several treatment lines, alone or in combination with radiotherapy, in the event of tumoral progression. Recently, ASCO proposed guidelines for the management of these systemic therapy options according to clinical parameters and BRAF mutational status [6]. Assessment of therapeutic efficacy and tolerance, in metastatic patients, is usually made quarterly, requiring a whole-body imaging including brain imaging, mostly assessed with brain MRI.

However, as opposed to other solid tumours, neither ESMO [7] nor ASCO [6] guidelines provide recommendations regarding which modality should be used for the extra-cerebral follow-up of metastatic melanoma patients treated with either TKIs or ICIs. 18F-FDG PET/CT has been proven to have high diagnostic performance for the detection of soft-tissue, nodal and visceral metastases at initial staging or during follow-up [8]. 18F-FDG PET/CT can identify tumour response early in the course of TKI treatment [9], for example as early as 15 days after initiation of Vemurafenib treatment [10]. In the framework of immunotherapy, 18F-FDG PET/CT has the unparalleled capability of assessing tumour response on a whole-body basis, and detecting signs of immune activation as well as immune-related adverse effects (irAEs) [11-17]. However, ceCT remains the standard for therapeutic trials, may be more easily available at some centres and ensures lower cost.

At our institution, all patients with metastatic melanoma under systemic therapy are followed-up with baseline and quarterly evaluation throughout the follow-up under treatment, with a combination of contrast-enhanced CT scan (ceCT), 18F-FDG PET/CT and brain MRI. There is no difference in follow-up between patients on targeted therapy, immunotherapy or chemotherapy. The choice of this combination of imaging for extracerebral evaluation aims to exhaustively assess metastatic lesions. For each patient, a weekly multidisciplinary consultation meeting analyzed the quarterly assessment in order to decide on the continuation of treatment.
For patients receiving immunotherapy, $^{18}$F-FDG PET/CT is performed in an outpatient basis a few days before patients are hospitalized during one day to receive their treatment, the ceCT being performed during this hospitalization.

The aim of the present observational study was to perform a comprehensive analysis of discordances in the treatment response extra-cerebral evaluation of stage IV melanoma patients when using a combination of ceCT and $^{18}$F-FDG PET/CT, including the anatomical site(s) of discordance and the change(s) in patients' management induced by these discordances.

2. Materials and Methods

Study design (Fig 1)

We conducted a retrospective monocentric observational study over a 3-years period in metastatic or unresectable melanoma patients aged over 18, and who were referred for $^{18}$F-FDG PET/CT and ceCT in the framework of extra-cerebral therapy monitoring of ICIs or TKIs. Inclusion criteria were: (i) stage IV melanoma patients receiving ICIs or TKIs; (ii) availability of baseline $^{18}$F-FDG PET/CT and ceCT pair before systemic treatment (iii) first $^{18}$F-FDG PET/CT and ceCT treatment monitoring performed between January 1, 2017 and December 31, 2019. Institutional review board approval was obtained (ref CLERS 1690) and waived the need for informed signed consent. In accordance with the European General Data Protection Regulation, we sought approval to collect data for this work from the national committee for data privacy, with the registration no. 2081250 v 0.

Fig 1. Consort diagram defining the study population

$^{18}$F-FDG PET/CT protocol
Patient’s preparation in the PET unit and PET acquisition and reconstructions were performed as per the European Association of Nuclear Medicine (EANM) guidelines for PET tumour imaging [18], our PET unit being EANM research Ltd (EARL) accredited since 2015 [19,20]. $^{18}$F-FDG was injected after glucose level had been checked to be < 200 mg/dl in patients who had been fasting for at least 4 hours. Patients were provisionally scanned 60 minutes after tracer injection. They were scanned from the base of the skull to mid-thigh with the arms on their sides for upper limb melanoma patients, or whole-body scanned for patients with primary melanoma of the lower limb or in patients with known distal subcutaneous metastases.

Two different PET/CT scanners were used: a Vereos system (Philips Medical Systems. Cleveland OH) and a Biograph TrueV with extended field-of-view (Siemens Medical Solutions). Details regarding acquisition and reconstruction parameters can be found elsewhere [21].

**Diagnostic CT scan**

ceCT scans were performed at our institution according to local protocol involving injection of contrast media, except in the case of contraindication, followed by exploration of the chest and the abdomen.

**Extraction and quotation of $^{18}$F-FDG PET/CT and ceCT reports**

$^{18}$F-FDG PET/CT and ceCT reports were extracted from the patients’ medical records and analysed by 2 physicians in consensus. For patients with dissociated findings, i.e patients with a mix of responding and non-responding target lesions, $^{18}$F-FDG PET/CT or CT examinations were reviewed on a dedicated workstation and clinical benefit was evaluated, based on the tumour burden of progressing versus non-progressing lesions.

Examinations were finally classified as follows:

- with a clinical benefit: complete response, partial response, stable disease.
- with no clinical benefit: progressive disease.
- inconclusive

**Analysis of discordant findings between $^{18}$F-FDG PET/CT and ceCT scans**

Whenever a discordance was observed between $^{18}$F-FDG PET/CT and ceCT reports, the anatomical site responsible for this discordance was noted, and conclusions of the multidisciplinary staff meeting discussing this discordance were noted and categorized as follows:

- Biopsy of one of the anatomical sites/surgery
- Complementary radiological examination (such as MRI or echography)
- No change, follow-up
- Switch from one line of treatment to another
- Radiotherapy

**Statistical analysis**

Quantitative variables are presented as mean (SD). Quartiles of the evaluation time from treatment initiation were used to classify examinations as follows:

i) early assessment: < 6months,
ii) interim assessments: 6-10 months and 10-16 months and
iii) late assessments, > 16 months.

One examination per patient and per time point was kept. In case of patients’ multiple examinations per time frame, only the earliest was considered.

Concordance between ceCT and $^{18}$F-FDG PET/CT reports were evaluated using the Cohen’s kappa and the reported Kappa values were classified according to the Landis & Koch benchmark, as follows: 0.0-0.20: poor agreement
0.21-0.40: fair agreement
Fischer tests were used to seek associations between histoprog nostic characteristics and the occurrence of discordances between ceCT Vs 18 F-FDG PET/CT.

For all statistical tests, a two-tailed P value of less than 0.05 was considered statistically significant. Graphs and statistical analysis were performed on XLSTAT Software (XLSTAT 2017: Data Analysis and Solution for Microsoft Excel, Addinsoft, Paris, France (2017)).

3. Results

3.1. Patients’ demographics

After searching in our database, out of 132 patients screened, 80 patients met the criteria and were included. A detailed flow chart of patients’ inclusion can be seen in Figure 1. The mean age at diagnosis was 61 years (range: 23 – 89 years). Nodular melanoma and superficial spreading melanoma were the two most frequent subtypes, accounting for 20% and 37.5%, respectively. BRAF<sup>V600</sup> mutation was found in 34 patients (42.5%). Patients’ characteristics and histopronostic variables from the primary lesion are displayed in table 1.

| Variable \ Statistic | Categories | Frequency | Relative frequency (%) |
|----------------------|------------|-----------|------------------------|
| Gender               | Female     | 48        | 60.0                   |
|                      | Male       | 32        | 40.0                   |
| Location             | Lower limb | 20        | 25                     |
|                      | Upper limb | 16        | 20                     |
|                      | Trunk      | 15        | 18.8                   |
|                      | Head and Neck | 11   | 13.7                   |
|                      | No primary lesion | 11   | 13.7                   |
|                      | Others     | 7         | 8.8                    |
| Stage at diagnostic  | IA         | 4         | 5.0                    |
|                      | IB         | 7         | 8.8                    |
|                      | IIA        | 6         | 7.5                    |
|                      | IIB        | 16        | 20.0                   |
|                      | IIC        | 6         | 7.5                    |
|                      | IIIB       | 2         | 2.5                    |
|                      | IIIC       | 1         | 1.3                    |
|                      | IIID       | 4         | 5.0                    |
|                      | IV         | 15        | 18.8                   |
### Table

|                          | Value | Percentage |
|--------------------------|-------|------------|
| **na**                   | 7     | 8.8        |
| **Missing**              | 12    | 15.0       |
| **Histology**            |       |            |
| Acral Lentiginous Melanoma | 2     | 2.5        |
| Lentigo Malignant Melanoma | 1     | 1.3        |
| Nodular melanoma         | 16    | 20.0       |
| Superficial Spreading Melanoma | 30   | 37.5       |
| **Others**               | 9     | 11.3       |
| No primary lesion        | 11    | 13.8       |
| **Missing**              | 11    | 13.8       |
| **Breslow**              |       |            |
| in situ                  | 1     | 1.3        |
| 0.1 - 1                  | 7     | 8.8        |
| 1.01 - 2                 | 13    | 16.3       |
| > 2                      | 35    | 43.8       |
| **na**                   | 18    | 22.5       |
| **Missing**              | 6     | 7.5        |
| **Ulceration**           |       |            |
| No                       | 23    | 28.8       |
| Yes                      | 26    | 32.5       |
| **na**                   | 18    | 22.5       |
| **Missing**              | 13    | 16.3       |
| **Regression**           |       |            |
| No                       | 40    | 50.0       |
| Yes                      | 4     | 5.0        |
| **na**                   | 18    | 22.5       |
| **Missing**              | 18    | 22.5       |
| **Mitotic index**        |       |            |
| High                     | 16    | 20.0       |
| Low                      | 8     | 10.0       |
| **na**                   | 18    | 22.5       |
| **Missing**              | 38    | 47.5       |
| **BRAF mutation**        |       |            |
| Yes                      | 34    | 42.5       |
| No                       | 46    | 57.5       |

### 3.2. 18F-FDG PET/CT and ceCT scans

A total of 195 pairs was analysed. Mean (SD) time between each pair of 18F-FDG PET/CT and ceCT examinations was 10 (9.7) days.

For patients receiving immunotherapy, 18F-FDG PET/CT were always performed prior to ceCT.

For patients receiving TKI, 18F-FDG PET/CT were performed prior to ceCT in 80% of cases (58/72) and after ceCT in 20% (14/72). The occurrence of discordances was not statistically different in the group of patients in whom 18F-FDG PET/CT preceded ceCT (17/53), compared to the group in whom ceCT preceded 18F-FDG PET/CT (6/14) (P = 0.53).

18F-FDG PET/CT scans were quoted as complete metabolic response (CMR), PMR (partial metabolic response), SMD (stable metabolic disease), and progressive metabolic disease (PMD) in 26, 20, 6 and 43 %, respectively. No inconclusive report was noted. Dissociated responses occurred in 5 %.
ceCT scans were quoted as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) in 38, 24, 5 and 32%, respectively and were considered as inconclusive in 1%. No dissociated responses occurred. Fig.2 displays the repartition of responses for $^{18}$F-FDG PET/CT scans and ceCT. Fig.3 displays the repartition of responses for $^{18}$F-FDG PET/CT scans and ceCT when grouping responses based on clinical benefit.

Fig 2. Repartition of imaging response for $^{18}$F-FDG PET/CT (left panels) and ceCT (right panels), categorized based on the time elapsed since introduction of treatment (defined as quartiles).
CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease

**Fig 3.** Repartition of imaging response for $^{18}$F-FDG PET/CT (left panels) and ceCT (right panels), categorized based on the time elapsed since introduction of treatment (defined as quartiles). Patients with a clinical benefit: complete response, partial response, stable disease. Patients with no clinical benefit: progressive disease.
Concordance between Ce CT Vs $^{18}$F-FDG PET/CT for treatment response classification was fair or moderate, except for the late interim evaluation where it was good (Kappa=0.68). When categorizing responses based on the clinical benefit, agreement between ceCT and $^{18}$F-FDG PET/CT was good, except for the early interim and late evaluations where it was moderate and fair, respectively. Table 2 displays kappa values in detail.

Table 2 Concordance between Ce CT Vs $^{18}$F-FDG PET/CT for treatment response classification

| Concordance (Cohen’s Kappa) | <6 months | 6-10 months | 10-16 months | >16 months |
|-----------------------------|-----------|-------------|--------------|------------|
| Clinical benefit* Vs no clinical benefit** | 0.73 | 0.51 | 0.67 | 0.39 |
| CR Vs SD Vs PR Vs PD Vs dissociated response | 0.43 | 0.38 | 0.68 | 0.34 |

CR, complete response; SD, stable disease; PR, partial response; PD, progressive disease.
* patients with clinical benefit: complete response, partial response, stable disease
** patients with no clinical benefit: progressive disease

3.3. Timeline, causes and consequences of discordances

Overall, discordances occurred in 65 cases (33%). When categorizing imaging based on the duration of treatment, discordances occurred in around a third of patients scanned for early therapy assessment (Fig 4a) and early interim evaluation (Fig 4b), decreased to 20% for late interim evaluations (Fig 4c) and increased to 57% for late evaluation (Fig 4d).
Fig 4 From left to right: repartition of discordance in imaging response between $^{18}$F-FDG PET/CT and ceCT, induced changes in patient’s management, and anatomical site responsible for the observed discordances.

Data are categorized based on the time elapsed since introduction of treatment (defined as quartiles) (a) early evaluation, (b) and (c) interim evaluation, (d), late evaluation.
When grouping categories of responses into two main categories (clinical benefit vs no clinical benefit), the number of discordances decreased from 65 (33%) to 38 (19%).

The main anatomical site of discordances between $^{18}$F-FDG PET/CT and ceCT scans were subcutaneous metastases, with a peak during early evaluation where this site represented 67% of discordances (Fig 4a). It was followed by liver, with a peak (22%) during late interim evaluation (Fig 4c).

Discordances between $^{18}$F-FDG PET/CT and ceCT scans were followed by no change in patient’s management in around two third of cases during the early and interim phase of treatment (Fig 4a-c), with an increase at 80% during late assessment (Fig 4d). In those cases, patients went on with the usual quarterly evaluation.

Neither histoprognostic variables nor location of the primary lesion were associated with the occurrence of discordances between ceCT and $^{18}$F-FDG PET/CT (Table 3).
Table 3  Impact of histoprognostic characteristics on the occurrence of discordance between ceCT Vs \(^{18}\) F-FDG PET/CT for treatment response classification

| Variables          | <6 months | 6 to 10 months | 10 to 16 months | >16 months | P value | Numbers of observation/discordances | P value | Numbers of observation/discordances | P value | Numbers of observation/discordances | P value |
|--------------------|-----------|----------------|-----------------|------------|---------|--------------------------------------|---------|--------------------------------------|---------|--------------------------------------|---------|
| **Location**       |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| Head/Neck/Trunk    | 55 / 18   | 0.500          | 56 / 20         | 0.600      | 0.970   | 48 / 13                              | 0.970   | 34 / 15                              | 0.688   |                                     |         |
| Lower limbs        |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| Upper limbs        |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| Others             |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| **Clinical stage** |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| I/II               | 42 / 14   | 1.000          | 40 / 12         | 0.720      | 1.000   | 34 / 7                               | 1.000   | 22 / 8                               | 0.649   |                                     |         |
| III/IV             |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| **Histological subtypes** |    |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| NMM                | 47 / 15   | 0.499          | 48 / 16         | 0.592      | 0.727   | 48 / 13                              | 0.727   | 30 / 13                              | 0.318   |                                     |         |
| SSM                |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| Others             |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| **BRAF status**    |           |                |                 |            |         |                                      |         |                                      |         |                                      |         |
| Mutated            | 55 / 18   | 0.394          | 56 / 20         | 0.762      | 0.360   | 41 / 9                               | 0.360   | 34 / 15                              | 0.715   |                                     |         |
|                          | Non-mutated       |             |             |             |             |             |             |
|--------------------------|-------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| **Breslow**              |                   |             |             |             |             |             |             |
| ≤1mm                     | 38 / 12           | 1.000       | 37 / 12     | 0.659       | 33 / 9      | 1.000       | 22 / 11     | 0.611       |
| >1mm                     |                   |             |             |             |             |             |             |
| **Ulceration**           |                   |             |             |             |             |             |             |
| Yes                      | 33 / 11           | 0.721       | 31 / 8      | 1.000       | 27 / 7      | 1.000       | 17 / 8      | 0.347       |
| No                       |                   |             |             |             |             |             |             |
| **Regression**           |                   |             |             |             |             |             |             |
| Yes                      | 31 / 10           | 0.967       | 27 / 7      | 1.000       | 25 / 6      | 1.000       | 16 / 8      | 0.200       |
| No                       |                   |             |             |             |             |             |             |
3.4. Impact of discordances on patient’s management

Most of the discordances (52/65, 80%) were due to $^{18}$F-FDG PET/CT scans upstaging the patient. Amongst these PET-related discordances, 17/52 (33%) led to change in patient’s management, the most frequent being radiotherapy of a progressing site. Switch from one line of treatment to another occurred only in one case during the late phase of treatment.

ceCT represented 13/65 (20%) of discordances and as opposed to $^{18}$F-FDG PET/CT, ceCT-induced changes in patients’ management were fewer (2/13, 15%).

Details regarding patient’s management can be found on Fig 5.

![Flowchart of changes in patients’ management related to discordances between $^{18}$F-FDG PET/CT and ceCT scans.](image-url)
Fig 6-9 displays representative examples of PET- or ceCT-related discordances.

Fig 6: 65-year-old male patient diagnosed with stage IV trunk melanoma (Breslow 0.7mm, BRAF+) and treated with Nivolumab. $^{18}$F-FDG PET/CT (a), maximum intensity view; (b) CT transverse slice; (c) PET transverse slice depicted progression of a subcutaneous nodule after 20 cycles of treatment, while ceCT determined stable disease. This patient was treated by radiotherapy.
Fig 7: 60-year-old female patient diagnosed with stage IV choroidal melanoma (BRAF-) treated with Nivolumab. (a), maximum intensity view; (b), low-dose CT from the PET/CT scan transverse slice; (c), diagnostic CT transverse slice; (d), PET transverse slice depicted progression of one pulmonary nodule after 3 cycles of treatment, while $^{18}$F-FDG PET/CT determined stable disease. Note the nodule overlooked on low-dose CT (b), and not $^{18}$F-FDG avid (d).
Fig 8: 50-year-old male patient diagnosed with stage IV melanoma of lower limbs (Breslow 0.6 mm, BRAF+) and treated with TKI. $^{18}$F-FDG PET/CT (a), maximum intensity view; (b,d) PET transverse slice; (c,e) CT transverse slice) depicted progression of carcinoma nodule after 19 months of treatment, while ceCT determined stable disease. This patient was switched to Nivolumab.
Fig 9: 65-year-old female patient diagnosed with stage IV choroidal melanoma and treated with Pembrolizumab. 

$^{18}$F-FDG PET/CT (b, e), PET transverse slice at the level of the liver target lesion; (a, d) PET maximum intensity view and corresponding CT transverse slice (c/f) are shown. CECT classified this patient as progressive based on RECIST 1 dimensions of the target lesion (red arrows) while PET considered this as stable metabolic disease based on the stability of tumour intensity. Immunotherapy was not withdrawn because of the lack of efficient second line therapy.

It is noteworthy that despite stability of tumour $^{18}$F-FDG uptake, the target lesion also displayed a significant increase in tumour metabolic, active tumour volume (MATV) and should therefore had been classified as progressive disease if PERCIST criteria [22] had been applied.

4. Discussion

While the therapeutic strategy is codified by recent guidelines [6,7], treatment monitoring of patients with melanoma remains at the discretion of clinicians and the availability of imaging. Numerous studies have shown the performance of PET in the staging of patients with melanoma [8,23,24], but few have discussed the added value of its use in treatment monitoring of ICIs [13,25,26] and TKIs [9]
in clinical routine and CeCT continues to be the gold standard in trials to assess extra-cerebral response.

Our study involved eighty patients and 195 pairs of $^{18}$F-FDG PET/CT and ceCT scans. Overall, discordances occurred in 65 cases (33%). It is noteworthy that the number of screened pairs was higher ($n=381$, see CONSORT flowchart on fig. 1) but we categorized patients referred for early assessment versus those referred for interim or late assessment, and excluded duplicate or triplicate pairs, leading to the final number of 195 pairs of $^{18}$F-FDG PET/CT and ceCT scans.

The findings from our study are 4-fold: (i) most of the observed discordances (80%) were related to $^{18}$F-FDG PET/CT findings and a third of these discordances led to a change in patient’s management (ii) neither histoprognostic variables nor location of the primary lesion were able to predict the occurrence of discordances between ceCT and $^{18}$F-FDG PET/CT (iii) ceCT led to fewer discordances and changes in patient’s management were scarce (iii) the more frequent anatomical site involved was subcutaneous for $^{18}$F-FDG PET/CT and lung or liver for ceCT. The latter point is due to the fact that subcutaneous lesions are easier to spot on $^{18}$F-FDG PET/CT and are often overlooked by CT or are even not part of the regions explored by CT when they are located on the limbs, as shown on Fig. 6. The superiority of ceCT is linked to the choice for many PET centres to use low-dose CT, i.e to perform CT only for attenuation correction and localization purposes. These low-dose CT are not adapted to the detection of small lung nodules. Finally, it should be noted that the readings of ceCT and $^{18}$F-FDG PET / CT are not supposed to be influenced by the age of the patients. Therefore, its influence on the occurrences of discrepancies has not been specifically studied here. However, age descriptive data in our series are representative of previous epidemiological reports [27].

Several reports have highlighted an increasing cost of treating melanoma, this increase being driven by an increased incidence of the disease and by introduction of expensive drugs [28-30]. For example, a recent study evaluating the cost of immunotherapies and targeted therapies in metastatic melanoma across 26 centres reported a cost multiplied by 104 since 2004 in France, drugs representing 80% of the total cost [29]. The high cost of treating advanced-stage melanoma obviously warrants the need to promote prevention and early detection, but also to optimize the use of systematic treatment, the latter requiring an appropriate use of imaging procedures for follow-up and treatment response evaluation. Indeed, in addition to drug cost, other costs such as extensive laboratory and imaging procedures have to be considered. An early diagnosis of progression will in theory allow withdrawal of an expensive therapy. In this study, therapeutic modifications consisted mostly of adding radiotherapy to non-responder metastatic sites. This management is supported by the search for an abscopal effect in the event of immunotherapy and the maintenance of a line of treatment [31].

Based on the findings from the present study, we have decided to modify our $^{18}$F-FDG PET/CT protocol that now includes an unenhanced lung diagnostic CT scan (acquired in deep inspiration and breath-hold), and to stop systematically performing ceCT, except in case contrast enhancement is required, such as for planning surgery. By proceeding this way, whole-body $^{18}$F-FDG PET/CT and brain MRI fully cover the metastatic spread patterns of melanoma.

In order to recommend this practice to other centres, a prospective study would be required. The design of a such study is likely to depend on which imaging test is the standard of care in a given Centre: in a Centre using ceCT as a standard, (1) PET/CT and ceCT would be blinded to each other, (2) planned patient’s management based on ceCT should be decided and (3) potential change in patients’ management based on PET/CT would then be prospectively recorded during tumour boards using standardized questionnaires [32,33] inquiring if and how PET/CT findings altered patient’s stage and their clinical management decisions. Ideally, (4) the relevance of induced changes should be evaluated.
When it comes to the few liver metastases overlooked by \(^{18}\text{F-FDG PET/CT, it is expected that advances in PET technology such as digital PET will improve detectability of such lesions} [34]. Moreover, in addition to its capability to perform whole-body assessment of disease extension, \(^{18}\text{F-FDG PET/CT is able to detect signs of immune activation with an excellent reproducibility} [16] and relevant immune-related adverse events, which may precede clinical diagnosis [12].

This study has several limitations. First, it was retrospective and the relevance of changes induced by imaging could not be assessed. However, the series of patients was extracted from a crosswise analysis between the Dermatology and Nuclear Medicine departments over a 3-years period and is therefore exhaustive. Also, we did not stratify our results based on the line or on the type of treatment. The fact that imaging reports were extracted from the patients’ medical records may be regarded as a bias, as radiologists may have had access to PET reports when interpreting ceCT, and vice versa. However, it is noteworthy that because of the patient’s management at our institution, patients receiving immunotherapy had always their PET/CT scan performed prior to the ceCT. This was also mostly the case for patients receiving TKI, and the occurrence of discordances was not statistically different whatever the order of scanning. Finally, the patient’s management in term of rhythm for follow-up at our centre does not necessarily reflect the situation at other centres. Although not being a limitation, it is noteworthy that the problematic of using ceCT in addition to \(^{18}\text{F-FDG PET/CT does obviously not apply to centres where a “one-stop-shop” \(^{18}\text{F-FDG PET/CT examination is performed using contrast enhancement for CT} [35].\)"

Author Contributions: Conceptualization, JB.LG, D.K and N.A.; methodology, D.K, C.L and N.A.; validation, D.K and N.A.; formal analysis, JB.LG, D.K, C.L and N.A.; investigation, JB.LG.; resources, C.N.; data curation, JB.LG, I.N, L.C., M.D.P, C.N.; writing—original draft preparation, D.K, C.L and N.A.; writing—review and editing, D.K, C.L and N.A.; supervision, D.K and N.A.; project administration JB.LG, and N.A.; All authors have read and agreed to the published version of the manuscript

Funding: This research received no external funding

Acknowledgments: Ms Helen Lapasset is thanked for English editing

Conflicts of Interest: The authors declare no conflict of interest

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA: a cancer journal for clinicians 2019, 69, 7-34.
2. Whiteman, D.C.; Green, A.C.; Olsen, C.M. The growing burden of invasive melanoma: Projections of incidence rates and numbers of new cases in six susceptible populations through 2031. The Journal of investigative dermatology 2016, 136, 1161-1171.
3. Grob, J.J.; Amonkar, M.M.; Karaszewska, B.; Schachter, J.; Dummer, R.; Mackiewicz, A.; Stroyakovskiy, D.; Drucis, K.; Grange, F.; Chiarion-Sileni, V., et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous braf val600-mutation-positive melanoma (combi-v): Results of a phase 3, open-label, randomised trial. The Lancet. Oncology 2015, 16, 1389-1398.
4. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England journal of medicine 2015, 373, 23-34.
5. Ribas, A.; Puzanov, I.; Dummer, R.; Schadendorf, D.; Hamid, O.; Robert, C.; Hodi, F.S.; Schachter, J.; Pavlick, A.C.; Lewis, K.D.; et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (keynote-002): A randomised, controlled, phase 2 trial. The Lancet. Oncology 2015, 16, 908-918.

6. Seth, R.; Messersmith, H.; Kaur, V.; Kirkwood, J.M.; Kudchadkar, R.; McQuade, J.L.; Provenzano, A.; Swami, U.; Weber, J.; Alluri, K.C., et al. Systemic therapy for melanoma: Asco guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020, Jco2000198.

7. Michielin, O.; van Akkooi, A.C.; Ascierto, P.A.; Dummer, R.; Keilholz, U. Cutaneous melanoma: Esms clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology 2019, 30, 1884-1901.

8. Reinhardt, M.J.; Joe, A.Y.; Jaeger, U.; Huber, A.; Matthies, A.; Bucerius, J.; Roedel, R.; Strunk, H.; Bieber, T.; Biersack, H.J., et al. Diagnostic performance of whole body dual modality 18f-fdg pet/ct imaging for n- and m-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol 2006, 24, 1178-1187.

9. Wong, A.N.M.; McArthur, G.A.; Hofman, M.S.; Hicks, R.J. The advantages and challenges of using fdg pet/ct for response assessment in melanoma in the era of targeted agents and immunotherapy. European journal of nuclear medicine and molecular imaging 2017, 44, 67-77.

10. McArthur, G.A.; Puzanov, I.; Amaravadi, R.; Ribas, A.; Chapman, P.; Kim, K.B.; Sosman, J.A.; Lee, R.J.; Nolop, K.; Flaherty, K.T., et al. Marked, homogeneous, and early [18f]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in braf-mutant advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012, 30, 1628-1634.

11. Aide, N.; Hicks, R.J.; Le Tourneau, C.; Lheureux, S.; Fanti, S.; Lopci, E. Fdg pet/ct for assessing tumour response to immunotherapy : Report on the eanm symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging 2019, 46, 238-250.

12. Iravani, A.; Hicks, R.J. Imaging the cancer immune environment and its response to pharmacologic intervention, part I: The role of (18)f-fdg pet/ct. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020, 61, 943-950.

13. Iravani, A.; Osman, M.M.; Weppler, A.M.; Wallace, R.; Galligan, A.; Lasocki, A.; Hunter, M.O.; Akhurst, T.; Hofman, M.S.; Lau, P.K.H., et al. Fdg pet/ct for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European journal of nuclear medicine and molecular imaging 2020.

14. Marandino, L.; Capozza, A.; Bandini, M.; Raggi, D.; Fare, E.; Pederzoli, F.; Gallina, A.; Capitanio, U.; Bianchi, M.; Gandaglia, G., et al. Incidence and clinical impact of inflammatory fluorodeoxyglucose positron emission tomography uptake after neoadjuvant pembrolizumab in patients with organ-confined bladder cancer undergoing radical cystectomy. Eur Urol Focus 2020.

15. Prigent, K.; Aide, N. (18)f-fludeoxyglucose pet/computed tomography for assessing tumor response to immunotherapy and detecting immune-related side effects: A checklist for the pet reader. PET Clin 2020, 15, 1-10.

16. Prigent, K.; Lasnon, C.; Ezine, E.; Janson, M.; Coudrais, N.; Joly, E.; Cesaire, L.; Stefan, A.; Depontville, M.; Aide, N. Assessing immune organs on (18)f-fdg pet/ct imaging for therapy monitoring of immune checkpoint inhibitors: Inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. European journal of nuclear medicine and molecular imaging 2021.

17. Seban, R.D.; Moya-Plana, A.; Antonios, L.; Yeh, R.; Marabelle, A.; Deutsch, E.; Schwartz, L.H.; Gomez, R.G.H.; Saenger, Y.; Robert, C., et al. Prognostic 18f-fdg pet biomarkers in metastatic mucosal and
cutaneous melanoma treated with immune checkpoint inhibitors targeting pd-1 and ctla-4. European journal of nuclear medicine and molecular imaging 2020.

18. Boellaard, R.; Delgado-Bolton, R.; Oyen, W.J.; Giammarile, F.; Tatsch, K.; Eschner, W.; Verzijlbergen, F.J.; Barrington, S.F.; Pike, L.C.; Weber, W.A., et al. Fdg pet/ct: Eanm procedure guidelines for tumour imaging: Version 2.0. European journal of nuclear medicine and molecular imaging 2015, 42, 328-354.

19. Aide, N.; Lasnon, C.; Veit-Haibach, P.; Sera, T.; Sattler, B.; Boellaard, R. Eanm/earl harmonization strategies in pet quantification: From daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging 2017, 44, 17-31.

20. Weisman, A.J.; Bradshaw, T.J.; Namias, M.; Jeraj, R. Impact of scanner harmonization on pet-based treatment response assessment in metastatic melanoma. Physics in medicine and biology 2020.

21. Lasnon, C.; Coudrais, N.; Houdu, B.; Nganoa, C.; Salomon, T.; Enilorac, B.; Aide, N. How fast can we scan patients with modern (digital) pet/ct systems? Eur J Radiol 2020, 129, 10944.

22. Wahl, R.L.; Jacene, H.; Kasamon, Y.; Lodge, M.A. From recist to percist: Evolving considerations for pet response criteria in solid tumors. J Nucl Med 2009, 50 Suppl 1, 122S-150S.

23. Holtkamp, L.H.J.; Chakera, A.H.; Fung, S.; Stretch, J.R.; Saw, R.P.M.; Lee, K.; Ch’ng, S.; Gonzalez, M.; Thompson, J.F.; Emmett, L., et al. Staging 18f-fdg pet/ct influences the treatment plan in melanoma patients with satellite or in-transit metastases. Melanoma Res 2020, 30, 358-363.

24. Singnurkar, A.; Wang, J.; Joshua, A.M.; Langer, D.L.; Metser, U. 18f-fdg-pet/ct in the staging and management of melanoma: A prospective multicenter ontario pet registry study. Clinical nuclear medicine 2016, 41, 189-193.

25. Iravani, A.; Osman, M.M.; Weppler, A.M.; Wallace, R.; Galligan, A.; Lasocki, A.; Hunter, M.O.; Akhurst, T.; Hofman, M.S.; Lau, P.K.H., et al. Fdg pet/ct for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging 2020, 47, 2776-2786.

26. Ito, K.; Teng, R.; Schoder, H.; Humm, J.L.; Ni, A.; Michaud, L.; Nakajima, R.; Yamashita, R.; Wolchok, J.D.; Weber, W.A. (18)f-fdg pet/ct for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med 2019, 60, 335-341.

27. Matthews, N.H.; Li, W.Q.; Qureshi, A.A.; Weinstock, M.A.; Cho, E. Epidemiology of melanoma. In Cutaneous melanoma: Etiology and therapy, Ward, W.H.; Farma, J.M., Eds. Codon Publications

The Authors: Brisbane (AU), 2017.

28. Franken, M.G.; Leeneman, B.; Jochems, A.; Schouwenburg, M.G.; Aarts, M.J.B.; van Akkooi, A.C.J.; van den Berkmortel, F.; van den Eertwegh, A.J.M.; de Groot, J.W.B.; van der Hoeven, K.J.M., et al. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in the netherlands. Anti-cancer drugs 2018, 29, 579-588.

29. Kandel, M.; Allayous, C.; Dalle, S.; Mortier, L.; Dalac, S.; Dutriaux, C.; Leccia, M.T.; Guillot, B.; Saiag, P.; Lacour, J.P., et al. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the melbase cohort. Eur J Cancer 2018, 105, 33-40.

30. Noels, E.; Hollestein, L.; Luijkx, K.; Louwman, M.; de Uyl-de Groot, C.; van den Bos, R.; van der Veldt, A.; Grunhagen, D.; Wakkee, M. Increasing costs of skin cancer due to increasing incidence and introduction of pharmaceuticals, 2007-2017. Acta Derm Venereol 2020, 100, adv00147.

31. Stamell, E.F.; Wolchok, J.D.; Gnatic, S.; Lee, N.Y.; Brownell, I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013, 85, 293-295.
32. Grahek, D.; Montravers, F.; Kerrou, K.; Aide, N.; Lotz, J.P.; Talbot, J.N. [18f]fdg in recurrent breast cancer: Diagnostic performances, clinical impact and relevance of induced changes in management. *Eur J Nucl Med Mol Imaging* 2004, 31, 179-188.

33. Yap, C.S.; Seltzer, M.A.; Schiepers, C.; Gambhir, S.S.; Rao, J.; Phelps, M.E.; Valk, P.E.; Czernin, J. Impact of whole-body 18f-fdg pet on staging and managing patients with breast cancer: The referring physician’s perspective. *J Nucl Med* 2001, 42, 1334-1337.

34. Fuentes-Ocampo, F.; Lopez-Mora, D.A.; Flotats, A.; Camacho, V.; Sizova, M.; Abouzian, S.; Duch, J.; Fernandez, A.; Estorch, M.; Carrio, I. Digital versus analog pet/ct in patients with known or suspected liver metastases. *Nucl Med Commun* 2020.

35. Pfluger, T.; Melzer, H.I.; Schneider, V.; La Fougere, C.; Coppenrath, E.; Berking, C.; Bartenstein, P.; Weiss, M. Pet/ct in malignant melanoma: Contrast-enhanced ct versus plain low-dose ct. *European journal of nuclear medicine and molecular imaging* 2011, 38, 822-831.